Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Asset Writedowns and Impairment (2023 - 2025)

Core Laboratories (CLB) has 3 years of Asset Writedowns and Impairment data on record, last reported at -$609000.0 in Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment changed 0.33% year-over-year to -$609000.0; the TTM value through Sep 2025 reached $24000.0, down 98.58%, while the annual FY2024 figure was $1.1 million, 36.01% down from the prior year.
  • Asset Writedowns and Impairment reached -$609000.0 in Q2 2025 per CLB's latest filing, down from $643000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.1 million in Q1 2024 and bottomed at -$611000.0 in Q2 2024.
  • Average Asset Writedowns and Impairment over 3 years is $317000.0, with a median of $576000.0 recorded in 2023.
  • The widest YoY moves for Asset Writedowns and Impairment: up 377.34% in 2024, down 101.74% in 2024.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $576000.0 in 2023, then plummeted by 101.74% to -$10000.0 in 2024, then plummeted by 5990.0% to -$609000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were -$609000.0 in Q2 2025, $643000.0 in Q1 2025, and -$10000.0 in Q4 2024.